Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
Frost N, Bleckmann A, Griesinger F, Grohé C, Janning M, Kollmeier J, Reinmuth N, Sebastian M, Thomas M, Reck M. Frost N, et al. Clin Lung Cancer. 2023 Sep;24(6):568-572. doi: 10.1016/j.cllc.2023.04.009. Epub 2023 Apr 23. Clin Lung Cancer. 2023. PMID: 37169628 Clinical Trial.
Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N, Tessmer A, Schmittel A, van Laak V, Raspe M, Ruwwe-Glösenkamp C, Brunn M, Senger C, Böhmer D, Ochsenreither S, Temmesfeld-Wollbrück B, Furth C, Schmidt B, Neudecker J, Rückert JC, Suttorp N, Witzenrath M, Grohé C. Frost N, et al. Lung Cancer. 2018 Nov;125:164-173. doi: 10.1016/j.lungcan.2018.09.021. Epub 2018 Sep 25. Lung Cancer. 2018. PMID: 30429016
Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Non-Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent.
Rogasch JMM, Furth C, Chibolela C, Hofheinz F, Ochsenreither S, Rückert JC, Neudecker J, Böhmer D, von Laffert M, Amthauer H, Frost N. Rogasch JMM, et al. Among authors: frost n. Clin Lung Cancer. 2020 May;21(3):264-272.e6. doi: 10.1016/j.cllc.2019.10.001. Epub 2019 Oct 15. Clin Lung Cancer. 2020. PMID: 31839531
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Frost N, Zhamurashvili T, von Laffert M, Klauschen F, Ruwwe-Glösenkamp C, Raspe M, Brunn M, Ochsenreither S, Temmesfeld-Wollbrück B, Suttorp N, Grohé C, Witzenrath M. Frost N, et al. Clin Lung Cancer. 2020 Nov;21(6):e607-e621. doi: 10.1016/j.cllc.2020.05.014. Epub 2020 May 22. Clin Lung Cancer. 2020. PMID: 32620471 Clinical Trial.
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.
Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F. Frost N, et al. Ther Adv Med Oncol. 2021 Feb 9;13:1758835920980558. doi: 10.1177/1758835920980558. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33613692 Free PMC article.
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids.
Frost N, Kollmeier J, Misch D, Vollbrecht C, Grah C, Matthes B, Pultermann D, Olive E, Raspe M, Ochsenreither S, von Laffert M, Suttorp N, Witzenrath M, Grohé C. Frost N, et al. Clin Lung Cancer. 2021 Sep;22(5):411-422. doi: 10.1016/j.cllc.2021.02.001. Epub 2021 Feb 6. Clin Lung Cancer. 2021. PMID: 33648877
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma.
Frost N, Kollmeier J, Vollbrecht C, Grah C, Matthes B, Pultermann D, von Laffert M, Lüders H, Olive E, Raspe M, Mairinger T, Ochsenreither S, Blum T, Hummel M, Suttorp N, Witzenrath M, Grohé C. Frost N, et al. Transl Lung Cancer Res. 2021 Feb;10(2):737-752. doi: 10.21037/tlcr-20-958. Transl Lung Cancer Res. 2021. PMID: 33718018 Free PMC article.
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Jabbour SK, et al. Among authors: frost n. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print. JAMA Oncol. 2021. PMID: 34086039 Free PMC article.
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma.
Kirchner M, Kluck K, Brandt R, Volckmar AL, Penzel R, Kazdal D, Endris V, Neumann O, Seker-Cin H, Goldschmid H, Glade J, Allgäuer M, Kriegsmann M, Winter H, Muley T, Perner S, Frost N, Reck M, Fröhling S, Schirmacher P, Thomas M, Budczies J, Christopoulos P, Stenzinger A. Kirchner M, et al. Among authors: frost n. ESMO Open. 2021 Oct;6(5):100253. doi: 10.1016/j.esmoop.2021.100253. Epub 2021 Sep 3. ESMO Open. 2021. PMID: 34487971 Free PMC article.
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery.
Boch T, Frost N, Sommer L, Overbeck TR, Michaeli CT, Szuszies CJ, Rieckmann LM, Beumer N, Imbusch CD, Winter H, Thomas M, Roeper J, Janning M, Griesinger F, Wermke M, Loges S. Boch T, et al. Among authors: frost n. Lung Cancer. 2022 Feb;164:46-51. doi: 10.1016/j.lungcan.2021.11.009. Epub 2021 Nov 23. Lung Cancer. 2022. PMID: 34998106
201 results